---
title: "Xolair (omalizumab), all indications: Pharmacology questions"
description: "Pharmacology questions on Xolair (omalizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pharmacokinetics and Components. Questions: How is Xolair metabolized and eliminated? What are the inactive ingredients in Xolair? Does the Xolair prefilled syringe contain latex? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xolair/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab), all indications: Pharmacology questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)  
Indication pages: [Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)

## Pharmacokinetics

<a id="xolair-metabolism"></a>

### How is Xolair metabolized and eliminated?

> “Clearance of omalizumab involved IgG clearance processes as well as clearance via specific 
> binding and complex formation with its target ligand, IgE.  Liver elimination of IgG included 
> degradation in the liver reticuloendothelial system (RES) and endothelial cells.  Intact IgG 
> was also excreted in bile.  In studies with mice and monkeys, omalizumab:IgE complexes 
> were eliminated by interactions with Fcγ receptors within the RES at rates that were 
> generally faster than IgG clearance.”

Source: [XOLAIR: Prescribing information, page 29, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=29)

## Components

<a id="xolair-inactive-ingredients"></a>

### What are the inactive ingredients in Xolair?

> “Each 75 mg prefilled syringe or autoinjector delivers 75 mg omalizumab in 0.5 mL and 
> contains arginine hydrochloride (21.05 mg), histidine (0.68 mg), L-histidine hydrochloride 
> monohydrate (1.17 mg), and polysorbate 20 (0.2 mg) in Sterile Water for Injection (SWFI), 
> USP.  
> Each 150 mg prefilled syringe or autoinjector delivers 150 mg omalizumab in 1 mL and 
> contains arginine hydrochloride (42.1 mg), histidine (1.37 mg), L-histidine hydrochloride 
> monohydrate (2.34 mg), and polysorbate 20 (0.4 mg) in SWFI, USP.  
>
> Each 300 mg prefilled syringe or autoinjector delivers 300 mg omalizumab in 2 mL and 
> contains arginine hydrochloride (84.2 mg), histidine (2.74 mg), L-histidine hydrochloride 
> monohydrate (4.68 mg), and polysorbate 20 (0.8 mg) in SWFI, USP.”

Source: [XOLAIR: Prescribing information, page 27, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=27)

> “Each 1.2 mL of reconstituted solution also contains histidine (1.3 
> mg), L-histidine hydrochloride monohydrate (2.1 mg), polysorbate 20 (0.4 mg) and sucrose 
> (108 mg).”

Source: [XOLAIR: Prescribing information, page 27, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=27)

<a id="xolair-latex"></a>

### Does the Xolair prefilled syringe contain latex?

> “The needle cap on the prefilled syringe (colored plunger rod) does not contain any latex.”

Source: [XOLAIR: Administration | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/dosing-and-administration/administration.html#:~:text=The%20needle%20cap%20on%20the,does%20not%20contain%20any%20latex.)

## Related pages
- [Medical information: Xolair (omalizumab): All indications](https://www.evicenter.com/medical-information/xolair)
- [Indication](https://www.evicenter.com/medical-information/xolair/indication)
- [Safety](https://www.evicenter.com/medical-information/xolair/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/xolair/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/xolair/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xolair/access-and-coverage)
